Sarepta Therapeutics

Valuation Analysis

About the Company

Sarepta Therapeutics en bref

Sarepta Therapeutics (SRPT) is currently trading at 15,28 € with a market capitalization of 1,6 Md €. The trailing P/E ratio stands at 50.09x, with a forward P/E of 6.43x. The 52-week range spans from 9,08 € to 22,07 €; the current price is 30.8% below the yearly high. Year-over-year revenue growth stands at -1.9%. The net profit margin stands at 2.98%.

💰 Dividende

Sarepta Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

23 analystes évaluent Sarepta Therapeutics (SRPT) au consensus : None. L'objectif de cours moyen est de 19,18 €, soit un potentiel de +25.5% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 4,36 € à 33,13 €.

Sarepta Therapeutics : la thèse d'investissement en détail

Sarepta Therapeutics (SRPT) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -1.9% year-over-year — until that trend reverses, valuation is exposed to further downgrades. With a net margin of just 2.98%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion.

Valorisation en contexte

The EV/EBITDA multiple of 44.6x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 6.43x is meaningfully below the trailing 50.09x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 25.5% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (28.53%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Sarepta Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.